>80,000 men). We then reviewed current treatment practices, and assessed what impact PREDICT Prostate would have on these.
INTRODUCTION AND OBJECTIVES:
To understand the decision making process in men diagnosed with localised prostate cancer (LPC) who are attending a combined clinic (CC), deciding between robotic prostatectomy and radiotherapy.
METHODS: Men diagnosed with clinically significant LPC who were suitable for either robotic assisted radical prostatectomy (RP) or radiotherapy (RT) were eligible for recruitment. Participants attended a CC at a tertiary referral centre (Liverpool Hospital, Sydney), where they consulted a urologist and radiation oncologist regarding treatment options.
A mixed-methods design was used. Initial treatment preferences and final treatment choices were collected via questionnaires. Consultations at the CC were audio-recorded and transcribed verbatim. Consultations were analysed in NVivo using a study-specific coding framework. A sub-set of participants (n [ 25) completed semistructured interviews outlining their beliefs, values and decisionmaking process. Interviews were thematically analysed.
RESULTS: Fourty-one patients who were approached (89%) consented to participate in this study (n[2 declined; n[3 nonresponders). Patient mean age was 66 years old. Mean pre-op PSA was 9.1. The most prevalent grade was ISUP grade II (47%) followed by ISUP III (19%).
Twenty-eight (68%) participants ultimately chose robotic prostatectomy (RP), 12 (29%) chose radiotherapy (RT), and 1 (2%) deferred treatment. Initial treatment preference was recorded in 36 patients. 17 out of 21 (81%) patients with an initial preference ultimately retained their original choice, whilst 4 (19%) patients changing their preference from RP to RT. In the 13 patients who were unsure about treatment before the CC, 8 (62%) subsequently chose RALP, and 5 (38%) chose RT.
Interviews revealed that treatment choice is largely dependent on clinicians' recommendations and participants did not routinely compare specific side effects of each treatment. In patients who were undecided or changed preference, factors which played a significant role in decision-making included treatment delivery, side effects, age and comorbidities (71% of patients). There was a strong patient belief that robotic prostatectomy provided a more definitive cure (74% of RP patients), whilst older men preferred radiotherapy as it had a perceived lesser impact on lifestyle (66% of RT patients).
CONCLUSIONS: Men who already had an initial treatment preference were unlikely to change their ultimate decision following the combined clinic consultation. In undecided patients, tailored discussion focusing on patient and treatment factors contributed to their treatment choice. Early involvement in a combined clinic can benefit the undecided patient in making a balanced and informed decision.
Source of Funding: None

PD63-09 UTILIZATION OF PSYCHIATRIC RESOURCES PRIOR TO GENITOURINARY (GU) CANCER DIAGNOSIS: IMPLICATIONS FOR SURVIVAL OUTCOMES
Zachary Klaassen*, Augusta, GA; Christopher J. D. Wallis, Hanan Goldberg, Toronto, Canada; Thenappan Chandrasekar, Philadelphia, PA; Rashid K. Sayyid, Augusta, GA; Stephen B. Williams, Galveston, TX; Kelvin A. Moses, Nashville, TN; Martha K. Terris, Augusta, GA; Robert K. Nam, Paul Kurdyak, Girish S. Kulkarni, Toronto, Canada INTRODUCTION AND OBJECTIVES: There is emerging evidence that oncology patients with pre-existing mental illness may have poorer survival compared to patients without psychiatric disease. Furthermore, cancer diagnosis may be associated with an increased risk of suicide. However, studies published thus far have failed to account for utilization of psychiatric resources, which may confound this relationship. The objective of this study was to (i) assess the impact of psychiatric utilization (PU) prior to cancer diagnosis on cancer-specific mortality (CSM), and (ii) to assess the effect of cancer diagnosis on suicide risk compared to the general population, accounting for pre-diagnosis PU.
METHODS: All residents of Ontario, Canada diagnosed with either prostate, bladder or kidney cancer (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) were included. Each patient was assigned a psychiatric utilization gradient (PUG) score in the five years prior to cancer diagnosis: 0 (none), 1 (outpatient), 2 (emergency department), 3 (hospital admission). First, a multivariable cause-specific hazard model was used to assess the effect of PUG score on CSM. Second, non-cancer controls were matched 4:1 to cancer patients based on sociodemographic variables and a marginal cause-specific hazard model was used to assess the effect of cancer on the risk of suicidal death. RESULTS: 191, 068 patients were included (137, 699 prostate, 29, 884 bladder, 23, 485 kidney cancer): 109, 154 (57.1%) with PUG score 0, 79,553 (41.6%) PUG score 1, 1,596 (0.84%) PUG score 2, and 765 (0.40%) PUG score 3. Increasing pre-diagnosis PU was associated with increased CSM: HR 1.78 (95%CI 1.47-2.14) among patients with PUG score 3 (vs 0) and HR 1.14 (95%CI 0.99-1.32) among those with PUG score 2. These patients with GU malignancies were then matched to 528,387 controls without any cancer diagnosis. Patients with GU cancer had a higher risk of dying of suicide compared to controls (HR 1.16, 95%CI 1.00-1.36). Specifically, among individuals with PUG score 0, those with cancer were significantly more likely to die of suicide compared to patients without cancer (HR 1.39, 95%CI 1.12-1.74).
CONCLUSIONS: Pre-cancer diagnosis PU is associated with worse CSM following diagnosis among patients with GU malignancies, with a graded effect. Additionally, the cancer diagnosis confers an Vol. 201, No. 4S, Supplement, Monday, May 6, 2019 THE JOURNAL OF UROLOGY Ò e1115
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